which MAGP2 had previously been shown to reduce or increase Notch signaling 116 respectively [11] . As shown in figure 1A , both cell lines expressed Notch receptors 1, 3, 117 and 4 and also shared expression of Notch ligands Jagged1 and 2 (JAG1, 2). However, 118 expression of Notch ligands Delta-like 1 and 3 (Dll1, 3) MAGP2 and compared Hes-1 promoter activity in the presence of RGD and RGE 165 versions of MAGP2. The mutation was confirmed by sequence analysis (Fig 2B) and 166 recombinant proteins were purified from bacterial cells by anti-FLAG chromatography 167 (Fig 2C) . The functional outcome of the mutation was confirmed by comparing 168 endothelial cell adhesion to RGD or RGE versions of the purified proteins. Purified 169 proteins were coated onto cell culture plates and remaining binding sites were blocked 170 with BSA. As anticipated, HMEC endothelial cells successfully adhered to both 171 MAGP2-RGD and positive control fibronectin, but failed to adhere to MAGP2-RGE or 172 BSA negative control indicating that the RGD domain is the sole binding site for HMEC 173 endothelial cells on MAGP2 (Fig 2D) . HMEC cells were subsequently transfected with 174 the Hes-1 luciferase reporter and either RGD or RGE versions of MAGP2 cDNAs to 175 monitor Notch signaling activity. As previously shown, MAGP2-RGD suppressed Hes-1 176 promoter activity. Surprisingly, MAGP2-RGE had a completely opposite effect and 177 increased Notch signaling (Fig 2E) 
268
At least eight of the 24 known integrin heterodimers have affinity for RGD motifs [2] . 269 Therefore, we used RT-PCR to compare expression of α and β integrin subunits known 270 to heterodimerize into RGD binding integrins in HMEC cells [2] . HMEC cells expressed 271 α2, α5, αV, β1, β3, and β6 subunits (Fig. 4A) . Both MAGP2 and EGFL7 had previously 272 been shown to interact with αvβ3 integrins but not with β1 integrins [6, 12] leading to the 273 hypothesis that β3 but not β1 integrins would interact with Notch signaling. To test this 274 hypothesis, we cultured HMEC endothelial cells in the presence of 0.5 to 2.0 µg/ml of β3 275 or β1 blocking antibodies and used western blot analysis to monitor Notch activation via 276 N1ICD fragment accumulation in whole cell lysates. As shown in figure 4B and 4C, 7H2 277 β3 blocking antibodies that had previously been shown to block β3 integrin mediated 278 adhesion [16] dose-dependently enhanced N1ICD accumulation. In contrast, P5D2 β1 279 blocking antibodies that had previously been shown to block β1 integrin mediated 280 adhesion [17] induced N1ICD accumulation at low dose (0.5 µg/ml), although higher 281 concentrations of β1 blocking antibodies failed to significantly affect N1ICD 282 accumulation. We next transfected HMEC cells with the Hes-1 luciferase reporter and 283 monitored Hes-1 promoter activity in the presence or absence of blocking antibodies 284 directed against β3 or β1 integrins. Interestingly, application of both β3 and β1 blocking 285 antibodies dose-dependently increased Hes-1 promoter activity across all tested antibody 286 concentrations (0.5 to 2.0 µg/ml) (Fig 4D) . Moreover, this activity was not restricted to 287 the Hes-1 promoter since both β3 and β1 blocking antibodies also enhanced promoter 288 activity from the Notch responsive Hes-5 and synthetic 4X-CSL promoters at 2.0 µg/ml 289 (Fig 4E) . Since HMEC cells also expressed β6 integrin, we also examined HES-1 290 promoter activity in the presence of 10D5 αvβ6 blocking antibodies but did not observe a 291 significant change in reporter activity (data not shown). Collectively these results 292 confirmed our hypothesis that β3 integrins couple to the Notch signaling pathway, and 293 also suggested that β1 integrin couples to Notch signaling via a mechanism that has 294 similarities, but may also have distinctions compared to β3 -Notch signaling. 295 (Fig 1) . Instead, mutation of the MAGP2 RGD domain to a non-340 integrin binding RGE domain not only eliminated the ability of MAGP2 to suppress 341 Notch signaling in endothelial cells, but also imbued MAGP2 with the ability to promote 342 Notch signaling in endothelial cells (Fig 2) . Combining these results and the results of 343 Miyamoto et al [10] which demonstrated that the C-terminal of MAGP2 is necessary to 344 promote Notch signaling in 3T3 cells, we now hypothesize that MAGP2 controls Notch 345 signaling with a two-part mechanism. In cells expressing MAGP2 binding integrins (i.e. signaling activity independently of Notch1, Jagged1, or Dll4 expression (Fig 3) . 372
Therefore, instead of controlling Notch signaling via increased Notch receptor or ligand 373 expression, our results suggest that integrin ligation directly engages in cross-talk with 374 Notch. Support for this mechanism has been published elsewhere. Suh et al., [22] 375 demonstrated that collagen1 increases NICD accumulation via interactions with α2b1 376 integrins, Mo et al., [23] observed that the downstream integrin regulator ILK (Integrin 377 linked Kinase) decreases Notch signaling by stimulating ubiquitination and rapid 378 degradation of the active Notch1 NICD fragment, and Ma et al., [24] found that the 379 kinase domain of SRC binds to the ankyrin domain of active NICD. Finally, a recent 380 screen to find genetic interactions with Notch identified a signaling mechanism involving 381 Notch, SRC, and JNK that was important for normal eye development in drosophila [25] . 382
Further investigation will be required to determine the mechanism by which integrins 383 couple to Notch signaling, however it is worth noting that SRC and ILK are well known 384 downstream effectors of integrins [3] . 385
386
Our results not only suggest that integrins control Notch signaling, but that signaling 387 through β1 and β3 integrins differentially controls Notch. We found that blocking 388 antibodies against β3 and β1 integrins both increased Hes-1, Hes-5, and 4X-CSL 389 promoter activity while β3 but not β1 blocking antibodies dose-dependently increased 390 N1ICD accumulation (Fig 4) . While we don't know how β3 and β1 integrins 391 differentially control Notch, this observation is consistent with previous work showing 392 that β1 and β3 integrins have both overlapping and independent mechanotransduction 393 activities in cells [26] [27] [28] . Building on this idea is the fact that β1 and β3 ligands often 394 have distinct spatiotemporal distributions in tissues. For instance, β1 ligands such as 395 laminins and collagen 4 are enriched in angiostatic vascular basement membranes [29] , 396 while β3 ligands such as vitronectin, fibronectin, and fibrin are enriched in pro-397 angiogenic provisional matrices [30] .
Therefore, we speculate that diverse 398 microenvironments differentially regulate Notch in response to cellular integrin 399 expression profiles and the local extracellular matrix composition. 400
401
Future experiments will need to determine the scope to which ECM proteins in the 402 microenvironment influence angiogenesis through Notch signaling, but it is noteworthy 403 that a number of ECM proteins have been shown to regulate Notch signaling and to 404 interact with either β3 integrins (e.g. EGFL7 [12, 13] and MAGP2 [6, 7, 11] or with β1 405 integrins (e.g. CCN3 [31, 32] and Reelin [33, 34] ). Finally, additional observations have 406 demonstrated that Notch1 and β1 integrin co-localize in neural stem cells [35] and thatactivation of Notch signaling can control β1 integrin affinity [36, 37] suggesting the
